Treatment and Clinical Outcome of a Patient With Spindle Cell Rhabdomyosarcoma Harboring MEIS1-FOXO1 Gene Fusion

Area of Science:

• Oncology
• Molecular Diagnostics
• Genetics

Background:

• Fusion-driven extraosseous spindle cell rhabdomyosarcoma (SRMS) is a rare subtype with limited treatment data.
• Understanding the molecular basis of SRMS is crucial for developing targeted therapies.

Observation:

• A unique case of SRMS in a 40-year-old female patient was identified.
• The tumor harbored a novel MEIS1-FOXO1 gene fusion, confirmed through molecular diagnostics.

Findings:

• The patient was successfully treated with a multimodal approach including surgery, radiation, and chemotherapy.
• This regimen followed a low-risk rhabdomyosarcoma treatment paradigm.

Implications:

• This case underscores the importance of molecular diagnostics in identifying rare gene fusions in SRMS.
• The successful management strategy may inform future treatment protocols for similar rare rhabdomyosarcoma subtypes.